# Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy

Study · id `cardio:ct-nct02891850` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02891850](<https://clinicaltrials.gov/study/NCT02891850>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02891850

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 225 participants.

## Technical summary

Registry record NCT02891850. Randomized; no masking; primary purpose treatment. Start 2017-01-11 (actual); primary completion 2020-01-29 (actual). Results posted on 2021-01-22.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 225 participants (enrolled count; ClinicalTrials.gov record NCT02891850, source copy `cardio:ctgov-nct02891850-2021-02-26`, retrieved 2026-10-31)
- Started: 2017-01-11 (actual) (ClinicalTrials.gov record NCT02891850, source copy `cardio:ctgov-nct02891850-2021-02-26`, retrieved 2026-10-31)
- Primary completion: 2020-01-29 (actual) (ClinicalTrials.gov record NCT02891850, source copy `cardio:ctgov-nct02891850-2021-02-26`, retrieved 2026-10-31)
- Completion: 2020-03-03 (actual) (ClinicalTrials.gov record NCT02891850, source copy `cardio:ctgov-nct02891850-2021-02-26`, retrieved 2026-10-31)
- Results first posted: 2021-01-22 (ClinicalTrials.gov record NCT02891850, source copy `cardio:ctgov-nct02891850-2021-02-26`, retrieved 2026-10-31)
- Countries: United States; Austria; Belgium; Brazil; Canada; Czechia; Denmark; France; Germany; Greece; Italy; Japan; Mexico; Netherlands; Poland; Portugal; South Korea; Spain; Taiwan; Türkiye; United Kingdom (ClinicalTrials.gov record NCT02891850, source copy `cardio:ctgov-nct02891850-2021-02-26`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02891850-2021-02-26`, retrieved 2026-10-31)

## The registry's words

- Brief title: Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy
- Acronym: REPLACE
- Condition: Pulmonary Arterial Hypertension
- Intervention (Drug): Riociguat (Adempas, BAY63-2521)
- Intervention (Drug): Sildenafil
- Intervention (Drug): Tadalafil
- Lead sponsor: Bayer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: Bayer (`cardio:bayer`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial (`cardio:pubmed-33773120`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 34be75d09e1890137e21ab9cb2f0c69da097f13ce335ebbb3946d48b7ea80fbf
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
